High-affinity immunoglobulin epsilon receptor-bound immunoglobulin E (FcεRI-bound IgE) (FcεRI-bound IgE)

The High-affinity immunoglobulin epsilon receptor-bound immunoglobulin E (FcεRI-bound IgE) complex is a critical molecular assembly on the surface of mast cells and basophils that mediates Type I hypersensitivity reactions. This complex is formed when monomeric IgE antibodies bind to the high-affinity FcεRI receptor, a process known as sensitization, which primes these effector cells for activation. Upon subsequent exposure to a multivalent allergen, the allergen cross-links the receptor-bound IgE molecules, triggering an intracellular signaling cascade involving kinases like Syk and BTK. This cascade leads to the rapid degranulation and release of inflammatory mediators such as histamine, leukotrienes, and cytokines, which drive the clinical symptoms of asthma, allergic rhinitis, and anaphylaxis. Therapeutically, this complex is targeted through several distinct strategies. Monoclonal antibodies like omalizumab and ligelizumab act by sequestering free IgE in the circulation, thereby preventing the formation of new IgE-FcεRI complexes and indirectly leading to the downregulation of surface receptor expression. More recently, disruptive agents such as DARPins (e.g., E2_79) and specific Fab fragments (e.g., NPB311) have been developed to actively dissociate preformed IgE from its receptor, offering the potential for a more rapid onset of clinical benefit. Additionally, small molecule inhibitors of downstream signaling components, such as BTK inhibitors, are being explored to block the effector phase of the allergic response initiated by this complex.

Other names

IgE-FcεRI complexReceptor-bound IgESensitized IgEMembrane-bound IgE-receptor complex

Active dissociation of preformed IgE-FcεRI complexes; Sequestration of free IgE to prevent complex formation; Inhibition of downstream signaling kinases; Co-aggregation with inhibitory receptors.